What is Lifesci Capital’s Forecast for MLTX Q4 Earnings?

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Stock analysts at Lifesci Capital boosted their Q4 2025 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a research report issued on Sunday, February 22nd. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($0.90) for the quarter, up from their prior estimate of ($1.14). The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Wednesday, February 25th. The company reported ($0.97) EPS for the quarter, hitting the consensus estimate of ($0.97). During the same quarter in the previous year, the business earned ($0.72) EPS.

A number of other research analysts have also recently issued reports on MLTX. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, February 3rd. Citigroup cut MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a report on Wednesday, October 29th. Oppenheimer raised their price objective on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Tuesday. BTIG Research boosted their target price on MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday. Finally, The Goldman Sachs Group downgraded MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and lifted their price target for the stock from $8.00 to $10.00 in a research note on Wednesday, January 14th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and five have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $27.15.

MoonLake Immunotherapeutics Stock Up 0.1%

MLTX stock opened at $18.22 on Wednesday. The company has a market cap of $1.17 billion, a P/E ratio of -5.49 and a beta of 1.21. MoonLake Immunotherapeutics has a 52 week low of $5.95 and a 52 week high of $62.75. The company’s 50-day moving average price is $15.47 and its 200 day moving average price is $23.57. The company has a current ratio of 8.50, a quick ratio of 8.50 and a debt-to-equity ratio of 0.25.

Institutional Trading of MoonLake Immunotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC boosted its holdings in MoonLake Immunotherapeutics by 3,343.2% in the first quarter. Millennium Management LLC now owns 344,320 shares of the company’s stock valued at $13,453,000 after acquiring an additional 334,320 shares during the last quarter. Jennison Associates LLC purchased a new position in shares of MoonLake Immunotherapeutics in the 2nd quarter worth about $2,941,000. Geode Capital Management LLC lifted its stake in shares of MoonLake Immunotherapeutics by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock valued at $2,809,000 after purchasing an additional 559 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of MoonLake Immunotherapeutics by 4,584.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 39,397 shares of the company’s stock valued at $1,860,000 after purchasing an additional 38,556 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of MoonLake Immunotherapeutics by 7.3% during the 2nd quarter. Legal & General Group Plc now owns 20,905 shares of the company’s stock worth $987,000 after purchasing an additional 1,425 shares during the period. 93.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Da Silva Jorge Santos sold 70,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total value of $1,014,300.00. Following the completion of the transaction, the chief executive officer owned 2,878,577 shares of the company’s stock, valued at $41,710,580.73. The trade was a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kristian Reich sold 72,908 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total transaction of $1,052,062.44. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 402,908 shares of company stock worth $5,987,162 over the last ninety days. 12.02% of the stock is owned by corporate insiders.

Trending Headlines about MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Multiple analyst price-target increases and buy ratings lifted sentiment — BTIG raised its target to $30 (buy) and Needham to $25 (buy), both implying meaningful upside from current levels. BTIG & Needham coverage (Benzinga)
• Positive Sentiment: Coverage noting a higher price target (reported as an 11.25% increase to $22.30) also supports near-term upside and analyst optimism. Price target increase report
• Positive Sentiment: New clinical data coverage described as “turning the tables” on sonelokimab, suggesting fresh positive data that could improve the drug’s commercial and regulatory outlook across inflammatory indications. MoonLake turns the tables on sonelokimab
• Neutral Sentiment: Analyst model update: Lifesci Capital narrowed its Q4 2025 EPS loss estimate (from ($1.14) to ($0.90)), reflecting slightly improved expectations but the company still projects a meaningful loss for the year. This reduces downside risk but doesn’t yet change profitability outlook materially.
• Negative Sentiment: One analyst note downgraded MLTX from Strong Buy to Buy after a mixed Phase 3 outcome (VELA‑2 missed its primary endpoint). The note highlights execution and regulatory uncertainty despite an FDA Type B meeting that left open a BLA path — this introduces near-term clinical and approval risk. Seeking Alpha downgrade coverage

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.